New York, NY, United States - AUGUST 31, 2026 - Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, is pleased to announce its comprehensive Untargeted Metabolomics Services, to provide researchers with unbiased, high-resolution metabolic profiling for a wide range of biological samples. These new services can enable scientists to uncover novel biomarkers, investigate metabolic pathways, and gain deeper insights into complex biological systems across basic, translational, and pharmaceutical research.
Metabolomics has become a key tool for understanding the effects of external or pathological stressors on biological systems. Over the past decade, both targeted and untargeted metabolomics have demonstrated tremendous potential. They enable the analysis of phenotypic changes in metabolites, and provide comprehensive information on the outcomes of normal physiological functions and the effects of various pathophysiological stimuli in tissues, cells, and bodily fluids. In the context of drug discovery, systems biology aims to combine 'omics' approaches with bioinformatics methods to enhance the success rate of drug candidate screening and the identification of clinical indications.
Untargeted metabolomics is a 'hypothesis-generating discovery strategy' that identifies metabolites and detects disturbances (including early signs of disease) by comparing sample groups (e.g. case versus control groups). Targeted metabolomics helps to gather critical information in the life sciences and reveals new strategies for treating major clinical diseases such as cancer, cardiovascular disease, diabetes and drug toxicity. Due to its importance in biomarker discovery, research is currently focused on enhancing the translational potential of non-targeted metabolomics.
Both approaches have their own advantages and disadvantages, and they are usually employed together to identify differentially expressed metabolites and accurately determine their masses. This enables in-depth research and analysis of metabolic biomarkers. Targeted and non-targeted metabolomics are widely used in the identification of foods, research into diseases, the validation of animal models, the discovery of biomarkers, the diagnosis of diseases, the development of drugs, the screening of drugs, the evaluation of drugs, and clinical research into plant and microbial metabolism.
Creative Diagnostics now offers untargeted metabolomics services based on high-resolution LC-MS/MS technology, supporting research projects in the pharmaceutical and biotechnology industries, academia, and translational research. Through the integration of optimized sample preparation, high-resolution mass spectrometry, advanced bioinformatics and biological interpretation, Creative Diagnostics has developed a thorough workflow that allows researchers to identify metabolic changes related to disease progression, drug responses and cellular functions.
The platform supports a wide range of applications, including global metabolite profiling, differential metabolite analysis, biomarker discovery, mechanism of action studies, drug efficacy assessment, host-pathogen interaction studies, immunometabolism research and multi-omics integration. Combining high-sensitivity LC-MS/MS data acquisition with robust statistical analysis, Creative Diagnostics' untargeted metabolomics services reveal metabolic pathway-level changes that are difficult to detect using targeted analysis methods alone.
Additionally, Creative Diagnostics implements rigorous quality control (QC) procedures throughout the analytical workflow to ensure consistent and reproducible data. These QC strategies include using pooled QC samples, monitoring system suitability to track instrument performance, normalizing with internal standards, and correcting for batch effects.
To learn more about Creative Diagnostics' Untargeted Metabolomics Services, please visit: https://qbd.creative-diagnostics.com/untargeted-metabolomics-services.html.
About Creative Diagnostics
Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.
Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
State: New York
Country: United States
Website: https://qbd.creative-diagnostics.com/
